# DESCRIPTION

## GRANT STATEMENT

- acknowledge government support

## TECHNICAL FIELD

- define technical field of diagnostics and therapeutics

## BACKGROUND

- introduce immune system response to cancer
- describe T cell function
- discuss evidence for immunotherapy
- summarize human tumor-reactive CTL reports
- introduce colorectal cancer
- describe symptoms and diagnosis of colorectal cancer
- discuss treatment and survival rates
- introduce importance of CTL recognition
- describe MHC-peptide complex interaction
- explain class I and class II MHC molecules
- discuss peptide association with MHC molecules
- describe antigen processing pathways
- introduce tumor antigens
- discuss immunotherapy approaches
- highlight need for identifying immunogens
- introduce phosphopeptides as attractive antigens
- discuss dysregulated phosphorylation in tumors
- describe phosphopeptide presentation on tumor cells
- summarize prior art on phosphopeptides
- highlight lack of studies on MHC class-I-bound phosphopeptides
- discuss limited evidence of human immune response
- conclude background section

## SUMMARY

- list embodiments of the presently disclosed subject matter
- mention variations and permutations of these embodiments
- describe compositions comprising at least one synthetic target peptide
- specify length of target peptides
- mention SEQ ID NOs: 1-177
- describe phosphorylated residues in target peptides
- describe replaced residues in target peptides
- mention non-hydrolyzable phosphate in compositions
- describe phosphoserine residues in target peptides
- specify immunological suitability of compositions
- describe target peptides capable of binding to MHC class I molecules
- specify MHC class I molecules
- describe target peptides derived from various proteins
- mention adjuvants in compositions
- specify adjuvants
- describe in vitro populations of dendritic cells
- describe in vitro populations of CD8+ T cells
- describe antibodies or antibody-like molecules
- specify binding members of antibodies or antibody-like molecules
- describe therapeutic agents linked to antibodies or antibody-like molecules
- describe T cell receptors
- describe in vitro populations of T cells transfected with mRNA
- describe methods for treating and/or preventing cancer
- describe administering compositions to patients
- specify target peptides in compositions
- describe methods for treating and/or preventing colorectal cancer
- describe administering CD8+ T cells to patients
- describe administering dendritic cells to patients
- describe methods for making cancer vaccines
- describe methods for screening target peptides
- describe methods for determining prognosis of cancer patients
- describe kits comprising target peptide compositions
- specify cytokines in kits
- specify adjuvants in kits
- describe additional peptides in kits
- describe methods for inducing target peptide-specific memory T cell responses
- specify adjuvants in methods
- describe treating proliferative disorders
- describe treating cancer

## BRIEF DESCRIPTION OF TABLES 3-9

- describe Tables 3-5
- describe Tables 6-9

## DETAILED DESCRIPTION

- define technical terms
- explain patent law conventions
- introduce target peptides

### I. Target Peptides

- relate to post-translationally modified immunogenic therapeutic target peptides
- define phosphopeptides
- describe target peptides as fragments of larger polypeptides
- specify length of target peptides
- describe phosphorylation of target peptides
- introduce modified target peptides
- describe substitutions in target peptides
- enhance immunogenicity of target peptides
- describe binding affinity of target peptides
- mix target peptides to form a cocktail
- link target peptides together
- use linkers between individual target peptides
- alter native amino acid residues
- enhance binding to MHC class I molecule
- measure immunogenicity of target peptides
- use transgenic mice to measure immunogenicity
- describe ADD Tg mice
- determine immunogenicity of modified phosphopeptides
- describe CD8+ T cells
- describe memory T cell response
- describe central memory T cells
- describe effector memory T cells
- describe T cell response
- describe target peptides as neo-antigens
- describe patient samples

### II. Phosphopeptides

- define phosphopeptides
- describe MHC class I- and MHC class II-specific phosphopeptides
- list MHC class I phosphopeptides
- describe phosphorylation of serine, homoserine, threonine, or tyrosine residues
- describe phosphopeptide mimetics
- describe IRS-2 over-expression in cancer
- describe Tensin 3 phosphopeptide
- describe phosphopeptide-specific memory T cell response

### III. Immunosuitablity

- introduce vaccine compositions
- describe HLA alleles prevalence
- define immunologically suitable peptides
- list target peptides for specific alleles
- describe composition coverage of population
- specify percentage of population coverage

### IV. Compositions

- define target peptide compositions
- specify formulation options
- list possible number of target peptides
- describe MHC class I specific target peptides
- mention additional target peptides
- specify purity requirements
- describe methods of production
- mention pharmaceutical acceptability
- describe loading dendritic cells
- form complexes with HLA molecules
- specify sequence homology
- describe sequence comparison algorithms
- mention adding additional proteins or peptides
- describe administration options
- specify goal of administration
- mention additional components
- specify recipients
- describe model systems
- introduce IV.A. Selection of Target Peptides
- describe finding of immune responses
- specify criteria for selecting target peptides
- introduce IV.B. Target Peptide Vaccines
- describe vaccine composition
- specify administration options
- describe prophylactic and therapeutic uses
- specify cancer types
- describe survival rate increases
- describe treatment response rates
- describe overall median survival
- describe tumor size decrease
- describe clinical tumor regression
- describe CTL response
- describe increase in progression free survival
- describe determining progression free survival, CTL response rates, clinical tumor regression rates, tumor size, survival rates, and/or response rates
- introduce adoptive cell transfer
- describe ACT therapies
- describe stimulating T helper cell or CTL response in vitro
- describe using loaded DCs to stimulate immune response
- describe treating cancer with cells pulsed with target peptides
- describe varying number of cells injected and antigen density
- introduce additional peptides present in target peptide compositions
- describe tumor-associated antigens
- list exemplary peptides derived from TAAs
- describe target peptide compositions or kits
- introduce tumor-specific peptides
- describe combination therapies
- list therapeutic agents
- specify cancer types
- describe chemotherapy for colorectal cancer
- introduce T cell potentiators
- describe PD1 antagonists
- specify dosages of PD1 antagonists
- list exemplary therapeutic agents
- specify dosages of therapeutic agents
- introduce cytokines
- list exemplary cytokines
- describe co-administration of cytokines
- specify dosages of cytokines
- describe delivery schedules of cytokines
- specify treatment cycles of cytokines
- describe overlapping schedules
- specify IL-2 dosages
- describe IL-2 administration schedules
- specify IL-2 units
- describe IL-2 treatment cycles
- conclude combination therapies

### V. Types of Proliferative Diseases

- list proliferative diseases
- specify cancer types
- detail colorectal cancer stages
- describe cancer spread
- list specific cancer types
- detail breast cancer types
- list genitourinary tract cancers
- list additional cancer types

### VI. Administration of Vaccine Compositions

- describe routes of administration
- list parenteral administration methods
- mention oral administration
- introduce formulations
- list pharmaceutical carriers
- describe additional substances for pH stabilization and adjuvants
- list adjuvants
- describe tetanus peptide characteristics
- specify tetanus peptide length
- describe tetanus peptide identity to wild type protein
- mention tetanus peptide binding to MHC Class II molecules
- describe modified tetanus peptides
- introduce polyinosinic-polycytidylic acid (Poly IC)
- describe Poly IC characteristics
- specify adjuvant dosage
- describe cyclophosamide administration
- introduce pharmaceutically acceptable salts
- describe acid salts preparation
- mention basic salts preparation
- list excipients
- specify pH range for administration
- discuss dosage considerations
- define therapeutically effective amount
- describe concentration of target peptides
- discuss solvents and diluents
- describe liposome structures
- specify single dose amounts
- specify total target peptide amounts
- discuss ratio of target peptides
- specify dosing frequency
- specify dosing intervals
- discuss course of treatment duration
- describe two-phase treatment approach
- specify initial phase duration
- specify subsequent phase duration
- describe dosage adjustment between phases
- specify dosage multiplier
- describe vaccine composition dosage
- specify administration schedule
- define kit components
- list kit container options
- describe lyophilized formulation
- outline reconstitution instructions
- specify storage conditions
- describe multi-use vial
- outline diluent options
- specify final peptide concentration
- describe kit materials
- outline co-administration options
- describe therapeutic kit components
- specify markers for efficacy
- describe immunohistochemistry
- outline flow cytometry
- describe ELISpot assay
- outline tetramer assay
- describe proliferation assay
- outline cytokine analysis

### VII. Antibodies and Antibody-Like Molecules

- introduce antibodies and antibody-like molecules
- describe therapeutic uses
- define antibody, antibody peptide, and antibody-like molecule
- describe antibody fragments
- introduce epitope
- define specific binding
- describe affinity constant
- broaden definition of antibody
- introduce soluble T cell receptor cytoplasmic domains
- describe conjugation to immunostimulatory peptides
- introduce CD3 antigen
- describe OKT3 antibody
- introduce ImmTAC
- describe native antibodies and immunoglobulins
- introduce disulfide bonds
- describe variable and constant domains
- introduce isolated antibodies
- describe purification methods
- introduce antibody mutants and variants
- describe sequence differences
- introduce variable domain
- describe complementarity determining regions
- introduce framework regions
- describe antigen binding site
- introduce antibody fragments
- describe Fab, Fab', F(ab')2, and Fv fragments
- introduce light chain types
- describe kappa and lambda light chains
- introduce immunoglobulin classes
- describe IgA, IgD, IgE, IgG, and IgM
- introduce heavy chain constant domains
- describe alpha, delta, epsilon, gamma, and mu
- introduce monoclonal antibodies
- describe hybridoma method
- introduce recombinant methods
- describe humanized antibodies
- introduce chimeric immunoglobulins
- describe humanization methods
- introduce fully human monoclonal antibodies
- describe trioma technique
- introduce human B-cell hybridoma technique
- describe EBV hybridoma technique
- introduce phage display libraries
- describe transgenic animals
- introduce human immunoglobulin loci
- describe antibody production in transgenic animals
- introduce therapeutic uses of humanized antibodies
- describe treatment protocols
- introduce transgenic non-human animals for producing human antibodies
- describe XENOMOUSE
- explain method for producing non-human animal lacking endogenous immunoglobulin heavy chain
- describe method for producing antibody of interest
- discuss use of antibodies in treating cancer
- explain detection of target peptides in biological samples
- describe antigens recognized by T cells
- discuss binding motifs for class I and II MHC molecules
- explain kits for diagnosis, monitoring, and prognosis of diseases
- describe conjugation of antibodies to therapeutic agents
- list alkylating agents
- list antimetabolites
- list natural products
- list mitotic inhibitors
- describe taxoids
- describe vinca alkaloids
- list antibiotics
- list miscellaneous agents
- discuss chemotherapeutic agents
- describe limitations of peptide-based vaccine approaches
- discuss antigens linked to transformation or oncogenic processes
- explain target peptides modified by intracellular modification
- discuss advantages of target peptides
- describe methods of identifying target peptides
- discuss target peptides displayed on transformed cells
- explain screening methods for target peptides
- describe method for inducing target peptide-specific memory T cell response
- discuss determining cancer disease prognosis
- explain correlation between target peptide-specific T cell response and prognosis
- describe examples of target peptides
- discuss use of target peptides in immunotherapy
- explain advantages of target peptides in immunotherapy
- describe methods for identifying target peptides for use in immunotherapy
- discuss target peptides associated with proteins involved in intracellular signaling cascades
- explain TCR reaction with phosphate groups on target peptides
- describe methods for inducing target peptide-specific T cell response
- discuss correlation between target peptide-specific T cell response and progression free survival

## EXAMPLES

- provide further illustrative embodiments

### Example 1

- identify MHC class-I-associated phosphopeptides
- characterize phosphopeptides using mass spectrometry
- assess TIL responses to phosphopeptides
- summarize TIL responses

### Example 2

- assess healthy donor PBMC responses to phosphopeptides

### Example 3

- establish phosphopeptide-specific T cell lines

### Example 4

- describe ELISpot analysis
- quantify T cell IFNÎ³ production
- envision T cell activation

### Example 5

- isolate and characterize phosphopeptides from CRC tumor samples
- assess TIL responses to phosphopeptides

